Mechanism of action of galantamine on N-methyl-D-aspartate receptors in rat cortical neurons

Journal of Pharmacology and Experimental Therapeutics

Volumn 310, Issue 3, 2004, Pages 933-942

  Moriguchi, Shigeki ^a   Marszalec, William ^a   Zhao, Xilong ^a   Yeh, Jay Z ^a   Narahashi, Toshio ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

7 CHLOROKYNURENIC ACID; ALPHA AMINO 3 HYDROXY 5 METHYL 4 ISOXAZOLEPROPIONIC ACID; CYCLIC AMP DEPENDENT PROTEIN KINASE; GALANTAMINE; GLYCINE; GUANINE NUCLEOTIDE BINDING PROTEIN; INHIBITORY GUANINE NUCLEOTIDE BINDING PROTEIN; KAINIC ACID; N [2 (4 BROMOCINNAMYLAMINO)ETHYL] 5 ISOQUINOLINESULFONAMIDE; N METHYL DEXTRO ASPARTIC ACID; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; PROTEIN KINASE C; STIMULATORY GUANINE NUCLEOTIDE BINDING PROTEIN;

ANIMAL CELL; ARTICLE; BRAIN NERVE CELL; CONCENTRATION RESPONSE; DRUG MECHANISM; DRUG POTENTIATION; DRUG RECEPTOR BINDING; EMBRYO; NERVE CELL CULTURE; NONHUMAN; PRIORITY JOURNAL; RAT;

ANIMALS; BINDING SITES; CELLS, CULTURED; CEREBRAL CORTEX; CYCLIC AMP-DEPENDENT PROTEIN KINASES; DRUG SYNERGISM; GALANTAMINE; GLYCINE; GTP-BINDING PROTEINS; N-METHYLASPARTATE; NEURONS; PROTEIN KINASE C; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, AMPA; RECEPTORS, KAINIC ACID; RECEPTORS, N-METHYL-D-ASPARTATE;

EID: 4243072971     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: 10.1124/jpet.104.067603     Document Type: Article

References (53)

1. Ascher P and Nowak L (1988) The role of divalent cation in the N-methyl-D-aspartate responses of mouse central neurones in culture. J Physiol (Lond) 399:247-266.
2. Barnes CA, Meltzer J, Houston F, Orr G, McGann K, and Wenk GL (2000) Chronic treatment of old rats with donepezil or galantamine: effects on memory, hippocampal plasticity and nicotinic receptors. Neuroscience 99:17-23.
3. Baxter MG, Lanthorn TH, Frink KM, Golski S, Wan R, and Olton DS (1994) d-Cycloserine, a novel cognitive enhancer, improves spatial memory in aged rats. Neurobiol Aging 15:207-213.
4. Ben-Ari Y, Aniksztein L, and Bregestovski P (1992) Protein kinase C modulation of NMDA currents: an important for LTP induction. Trends Neurosci 15:333-339.
5. Chen L and Huang LY (1991) Sustained potentiation of NMDA receptor-mediated glutamate responses through activation of protein kinase C by a mu opioid. Neuron 7:319-326.
6. 2+ block of NMDA-receptor channels as a mechanism of modulation. Nature (Lond) 356:521-523.
7. 2+ signals and neurotoransmitter release. Mol Pharmacol 64:1217-1226.
8. Dysken MW, Mendels J, and LeWitt P (1992) Milacemide; a placebo-controlled study in senile dementia of the Alzheimer type. J Am Geriatr Soc 40:503-506.
9. Fonnum F, Myhrer T, Paulsen RE, Wangen K, and Oksengard AR (1995) Role of glutamate and glutamate receptors in memory function and Alzheimer's disease. Ann NY Acad Sci 757:475-486.
10. Francis PT, Sims NR, Procter AW, and Bowen DM (1993) Cortical pyramidai neurone loss may cause glutamatergic hypoactivity and cognitive impairment in Alzheimer's disease: investigative and therapeutic perspectives. J Neurochem 60:1589-1604.
11. Giacobini E (2000) Cholinesterase inhibitor therapy stabilizes symptoms of Alzheimer's disease. Alzheimer Dis Assoc Disorders 14 (Suppl 1):S3-S10.
12. 3H]glutamate binding. J Neurochem 48:543-551.
13. Hanndelmann GE, Nevins ME, Mueller LL, Arnolde SM, and Cordi AA (1989) Milacemide, a glycine prodrug, enhances performance of learning tasks in normal and amnestic rodents. Pharmacol Biochem Behav 34:823-828.
14. Hoffman PW, Ravindran A, and Hunganir RL (1994) Role of phosphorylation in desensitization of acetylcholine receptors expressed in Xenopus oocytes. J Neurosci 14:4185-4195.
15. Huganir RL and Greengard P (1990) Regulation of neurotransmitter receptor desensitization by protein phosphorylation. Neuron 5:555-567.
16. Kelso SR, Nelson TE, and Leonard JP (1992) Protein kinase C-mediated enhancement of NMDA currents by metabotropic glutamate receptors in Xenopus oocytes. J Physiol (Lond) 449:705-718.
17. Kroll WJ, Sramek JJ, and Cutler NR (1999) Cholinesterase inhibitors: a therapeutic strategy for Alzheimer disease. Ann Pharmacotherapy 33:441-450.
18. Leonard AS and Hell JW (1997) Cyclic AMP-dependent protein kinase and protein kinase C phosphorylate N-methyl-D-aspartate receptors at different sites. J Biol Chem 272:12107-12115.
19. Logan SM, Rivera FE, and Leonard JP (1999) Protein kinase C modulation of recombinant NMDA receptor currents: roles for the C-terminal C1 exon and calcium ions. J Neurosci 19:974-986.
20. Maelicke A and Albuquerque EX (2000) Allosteric modulation of nicotinic acetylcholine receptors as a treatment strategy for Alzheimer's disease. Eur J Pharmacol 393:165-170.
21. Maelicke A, Samochocki M, Jostock R, Fehrenbacher A, Ludwig L, Albuquerque EX, and Zerlin M (2001) Allosteric sensitization of nicotinic receptors by galantamine, a new treatment strategy for Alzheimer's disease. Soc Biol Psychiatry 49:279-288.
22. Markram H and Segal M (1992) Activation of protein kinase C suppresses responses to NMDA in rat CA1 hippocampal neurones. J Physiol (Lond) 457:491-501.
23. Marszalec W and Narahashi T (1993) Use-dependent pentobarbital block of kainate and quiaqualate currents. Brain Res 608:7-15.
24. 2+ of NMDA responses in spinal cord neurones. Nature (Lond) 309:251-263.
25. Moriguchi S, Marszalec W, Zhao X, Yeh JZ, and Narahashi T (2003 a) Potentiation of N-methyl-D-aspartate-induced currents by the nootropic drug nefiracetam in rat cortical neurons. J Pharmacol Exp Ther 307:160-167.
26. Moriguchi S, Marszalec W, Zhao X, Yeh JZ, and Narahashi T (2003b) Alzheimer's drug nefiracetam modulates the activity of NMDA receptors in rat cortical neurons. Soc Neurosci Abstr 795.12.
27. Nabeshima T, Nakayama S, Ichihara K, Yamada K, Shiotani T, and Hasegawa T (1994) Effects of nefiracetam on drug-induced impairment of latent learning in mice in a water finding task. Eur J Pharmacol 255:57-65.
28. Nishizuka Y (1988) The molecular heterogeneity of protein kinase C and its implications for cellular regulation. Nature (Lond) 334:661-665.
29. Palmer AM (1996) Neurochemical studies of Alzheimer's disease. Neurodegeneration 5:381-391.
30. Palmer AM (2002) Pharmacotherapy for Alzheimer's disease: progress and prospects. Trends Pharmacol Sci 23:426-433.
31. Palmer AM and Gershon S (1990) Is the neurochemical basis of Alzheimer's disease cholinergic or glutamatergic? FASEB J 4:2745-2752.
32. 2+. Neuron 15:1109-1120.
33. Pereira EFR, Alkondon M, Reinhardt S, Maelicke A, Peng X, Lindstrom P, Whiting P, and Albuquerque EX (1994) Physostigmine and galanthamine: probes for a novel binding site on the α4∃2 subtypes of neuronal nicotinic acetylcholine receptors stably expressed in fibroblast cells. J Pharmacol Exp Ther 279:768-778.
34. Pereira EFR, Reinhardt-Maelicke, Schrattenholz A, Maelicke A, and Albuquerque (1993) Identification and functional characterization of a new agonist site on nicotinic acetylcholine receptors in cultured hippocampal neurons. J Pharmacol Exp Ther 265:1474-1491.
35. Raskind MA, Peskind ER, Wessel T, and Yuan W (2000) Galantamine in AD: A6-month randomized, placebo-controlled trail with a 6-month extension. The Galantamine USA-1 Study Group. Neurology 54:2261-2268.
36. Raymond LA, Tingley WG, Blackstone KW, and Huganir RL (1994) Glutamate receptor modulation by protein phosphorylation. J Physiol (Lond) 88:181-192.
37. Riekkinen P Jr, Ikonen S, and Riekkinen M (1998) D-Cycloserine, a partial NMDA receptor-associated glycine-B site agonist, enhances reversal learning, but a cholinesterase inhibitor and nicotine has no effect. Neuroreport 9:3647-3651.
38. Samochocki M, Hoffle A, Fehrenbacher A, Jostock R, Ludwig J, Christner C, Radina M, Zerlin M, Ullmer C, Pereira EF, et al. (2003) Galantamine is an allosterically potentiating ligand of neuronal nicotinic but not of muscarinic acetylcholine receptors. J Pharmacol Exp Ther 305:1024-1036.
39. Santos MD, Alkondon M, Pereira EF, Aracava Y, Eisenberg HM, Maelicke A, and Albuquerque EX (2002) The nicotinic allosteric potentiating ligand galantamine facilitates synaptic transmission in the mammalian central nervous system. Mol Pharmacol 61:1222-1234.
40. Schrattenholz A, Pereira EFR, Roth U, Weber KH, Albuquerque EX, and Maelicke A (1996) Agonist responses of neuronal nicotinic acetylcholine receptors are potentiated by a novel class of allosterically acting ligands. Mol Pharmacol 49:1-6.
41. Schwartz BL, Hashtroudi S, Herting RL, Handerson H, and Deutch SI (1991) Glycine prodrug facilitates memory retrieval in humans. Neurology 41:1341-1343.
42. Schwartz BL, Hashtroudi S, Herting RL, Schwartz P, and Deutsch SI (1996) d-Cycloserine enhances implicit memory in Alzheimer's patients. Neurology 46:420-424.
43. Snell LD, Iorio KR, Tabakoff B, and Hoffman PL (1994) Protein kinase C activation attenuates N-methyl-D-aspartate-induced increases in intracellular calcium in cerebellar granule cells. J Neurochem 62:1783-1789.
44. Tariot PN, Farlow MR, Grossberg GT, Graham SM, MacDonald S, and Gergel I (2004) Memantine treatment in patients with moderate to severe Alzheimer's disease already receiving donepezil: a randomized controlled trail. J Am Med Assoc 291:317-324.
45. Tariot PN, Solomon PR, Morris JC, Kershaw P, Lilienfeld S, and Ding C (2000) A 5-month, randomized, placebo-controlled trail of galantamine in AD. The Galantamine USA-10 Study Group. Neurology 54:2269-2276.
46. Thomson T, Kewitz H, Bickel V, Straschill M, and Holl G (1991) Preclinical and clinical studies with galantamine, in Cholinergic Basis of Alzheimer's Disease (Becker R and Giacobini E eds), pp 328-336, Birhauser, Boston.
47. Urushihara H, Tohda M, and Nomura Y (1992) Selective potentiation of N-methyl-D-aspartate-induced current by protein kinase C in Xenopus oocytes injected with rat brain RNA. J Biol Chem 267:11697-11700.
48. Vidal C and Changeux JP (1996) Neuronal nicotinic acetylcholine receptors in the brain. News Physiol Sci 11:202-208.
49. 2+-sensitivity of cloned NMDA receptors. Neuropharmacology 35:29-36.
50. Wang LY and MacDonald JF (1995) Modulation by magnesium of the affinity of NMDA receptors for glycine in murine hippocampal neurones. J Physiol (Lond) 486:83-95.
51. Woodruff-Pak DS and Hinchliffe RM (1997) Mecamylamine- or scopolamine-induced learning impairment: ameliorated by nefiracetam. Psychopharmacology 131:130-139.
52. Xiong ZG, Raouf R, Lu WY, Wang LY, Orser BA, Dudek EM, Browning MD, and MacDonald JF (1998) Regulation of N-methyl-D-aspartate receptor function by constitutively active protein kinase C. Mol Pharmacol 54:1055-1063.
53. Zhao X, Kuryatov A, Lindstorm JM, Yeh JZ, and Narahashi T (2001) Nootropic drug modulation of neuronal nicotinic acetylcholine receptors in rat cortical neurons. Mol Pharmacol 59:674-683.